DRG´s Hepcidin 25 (bioactive) HS Presented At ASH Annual Meeting, December 2015
DRG was proud to be a featured participant at American Society of Hematology (ASH) 2015, held in Orlando, FL from December 5 - 7, 2015! DRG showcased an expansive collection of its most cutting-edge products to the hematology community gathered at the ASH Annual Meeting including our:
NEW Hepcidin 25 (bioactive) HS Assay
The gold standard in Hepcidin Measurement
Now available on our DRG:HYBRiD-XL, a fully automated random access analyzer for Immunoassay and Clinical Chemistry as well as in the classic ELISA format
The optimized High Sensitive Hepcidin 25 assay includes several new features, such as:
- Better Sensitivity (dilution possible down to 0.153 ng/ml)
- Incubation steps at room temperature
- No incubator or shaker needed
- Total assay time of 2 hours
- Excellent correlation to Mass Spectrometry
- DRG HYE-5769 (DRG:HYBRiD-XL Assay) shows good correlation to EIA-5782 (Manual ELISA)
"DRG International, Inc. was proud to present at the ASH Annual Meeting for the second time," said Dr. Cyril E. Geacintov, founder, president and CEO of DRG International. "We were exceptionally pleased with the attention our new Hepcidin 25 (bioactive) HS ELISA received, including a poster presentation entitled ‘Iron Age or New Age: Ironing out the Diagnosis of Anaemia of Inflammation from Iron Deficiency Anaemia' by Mrs. Nicola Svenson."
Please see a link to Mrs. Svenson's poster here. The DRG Hepcidin 25 (bioactive) HS ELISA kit was also used in Dr. I. Papassotiriou's paper entitled "Assessment of Serum Bioactive Hepcidin-25, Soluble Transferrin Receptor and Their Ratio in Predialysis Patients: Correlation with the Response to Intravenous Ferric Carboxymaltose Administration." Dr. Papassotiriou is a PhD at the Aghia Sophia Children's Hospital in Athens, Greece.
